Skip to main content
. 2018 Sep 27;53(6):2503–2517. doi: 10.3892/ijo.2018.4577

Figure 1.

Figure 1

Overexpression of BRD4 in PCa cell lines and tumor specimens. (A) Data regarding the expression of BRD4 in 14 types of cancer was gathered from the Pan-Cancer Analysis Platform in TCGA Data Portal (starBase version 2.0). (B) RT-qPCR was used to analyze the transcription of BRD4 mRNA in human cancerous and paired normal prostate tissues from 46 patients with PCa. (C) Expression of BRD4 mRNA was significantly higher in patients with M-PCa compared with N-M PCa specimens. (D) Immunohistochemical analysis of BRD4 in PCa samples and surrounding normal prostate tissue. Magnification, ×400 and ×1,000. The average IOD was analyzed by Image-Pro Plus software. *P<0.05 vs. N prostate tissues. (E and F) mRNA and protein expression levels of BRD4 in RWPE1 cells (human prostate epithelial cell line), and DU145, PC3 and LNCAP cells (human prostate cancer cell lines) were evaluated by RT-qPCR and western blotting. *P<0.05 vs. RWPE1 cells. Data are presented as the mean ± standard deviation. Experiments were performed in triplicate. BRD4, bromodomain-containing protein 4; IOD, integrated optical density; M, metastatic; N, normal; N-M, non-metastatic; PCa, prostate cancer; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.